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Abstract
Background/Aims: The small molecule, Tolfenamic acid (TA) has shown anti-cancer activity 
in pre-clinical models and is currently in Phase I clinical trials at MD Anderson Cancer Center 
Orlando. Since specificity and toxicity are major concerns for investigational agents, we tested 
the effect of TA on specific targets, and assessed the cellular and organismal toxicity representing 
pre‐clinical studies in cancer. Methods: Panc1, L3.6pl, and MiaPaCa-2 (pancreatic cancer), 
hTERT-HPNE(normal), and differentiated/un-differentiated SH-SY5Y (neuroblastoma) cells 
were treated with increasing concentrations of TA. Cell viability and effect on specific molecular 
targets, Sp1 and survivin were determined. Athymic nude mice were treated with vehicle or 
TA (50mg/kg, 3times/week for 6 weeks) and alterations in the growth pattern, hematocrit, and 
histopathology of gut, liver, and stomach were monitored. Results: TA treatment decreased 
cell proliferation and inhibited the expression of Sp1 and survivin in cancer cells while only 
subtle response was observed in normal (hTERT-HPNE) and differentiated SH-SY5Y cells. Mice 
studies revealed no effect on body weight and hematocrit. Furthermore, TA regimen did not 
cause signs of internal-bleeding or damage to vital tissues in mice. Conclusion: These results 
demonstrate that TA selectively inhibits malignant cell growth acting on specific targets and 
its chronic treatment did not cause apparent toxicity in nude mice. 
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Introduction
Non-steroidal anti-inflammatory drugs (NSAIDs) are the most commonly prescribed 
drugs for the relief of pain and inflammation. The primary mechanism of action of NSAIDs 
is through inhibition of cyclooxygenase (COX) enzymes, and the subsequent inhibition of 
prostaglandin synthesis at the site of inflammation [1]. Arachidonic acid is converted to 
prostaglandins by two COX enzymes; COX-1 which is ubiquitously expressed, and COX-2 which 
is regulated by various stimuli associated with inflammation [2]. First generation NSAIDs 
were primarily COX-1 inhibitors and unfortunately have been associated with severe upper 
gastrointestinal (GI) toxicity. This phenomenon led to the development of COX-2 selective 
NSAIDs (coxibs) that cause less GI damage relative to the nonselective NSAIDs. However, 
use of certain coxibs is also under scrutiny as their long-term use has been associated with 
severe cardiovascular toxicity [3-5]. These concerns facilitated the recommendation for the 
withdrawal of Vioxx (Rofecoxib) and Bextra (Valdecoxib) from the US market [6-8]. Even 
though the risks associated with various NSAIDs are continuously being monitored, their 
multiple applications in clinical settings has led to studies that are focused on selecting less 
hazardous NSAIDs and optimizing low doses. Understanding precise molecular mechanisms 
associated with NSAID toxicity and developing less toxic NSAIDs is also in progress [9, 10]. 
NSAIDs also have been extensively evaluated for their application in cancer prevention 
and therapy. The anti-cancer activity of NSAIDs is well studied using pre-clinical models. 
For example, laboratory studies showed that NSAIDs and COX-2 inhibitors such as aspirin, 
indomethacin, sulindac and celecoxib suppressed tumor growth in animal models for multiple 
cancers including bladder, esophageal, lung, breast and pancreatic [11-16]. The interest in 
NSAIDs has been heightened by several studies that have suggested a chemopreventive 
response to long term use. Some of the strongest evidence comes from epidemiological 
studies which have shown the association of prolonged use of NSAIDs with a decrease in 
the incidence of certain malignancies [17-21]. There is growing evidence indicating an 
association between the use of NSAIDs and the decrease in cancer incidence and/or disease 
progression in breast, colorectal, lung and prostate cancers [22, 23].
Although the exact mechanisms of the anticancer activities of NSAIDs are unknown, 
experimental evidence suggests the involvement of both COX-dependent and independent 
pathways [24, 25]. Several COX-independent NSAIDs are currently in pre-clinical testing for 
the treatment or chemoprevention of specific cancers. Pre-clinical studies from our laboratory 
and others demonstrated the anti-cancer and chemopreventive response of tolfenamic acid 
(TA, 2-(4-chloro-3-methylanilino)benzoic acid) in a variety of human cancers. TA has been 
studied in pre-clinical models for adult (pancreatic [26, 27], lung [28], esophageal [14, 29], 
ovarian [30], prostate [31, 32], and colon [33, 34]) cancers and pediatric (leukemia [35], 
neuroblastoma [36], and medulloblastoma [37]) malignancies. Experimental results from 
our laboratory also showed a chemopreventive effect by this drug in an animal model of 
esophageal cancer [29, 38]. TA exhibits anticancer and chemopreventive activities primarily 
via inhibiting specificity protein (Sp) transcription factors. Cell culture studies revealed 
that by targeting specific Sp transcription factors (Sp1, Sp3 and Sp4), TA modulates the 
expression of key candidates such as c-PARP, caspases, cyclins, survivin, c-Met, and VEGF 
that are associated with apoptosis, cell cycle, angiogenesis and suppression of cellular 
growth. Previously we showed that TA acts as a radio-sensitization agent that increases 
tumor growth inhibition and decreases metastasis when used along with radiation [39]. TA 
is currently under study in a Phase I clinical trial at MD Anderson Cancer Center Orlando for 
upper gastro-intestinal cancers in combination with radiation therapy. 
TA is a commonly prescribed agent for treating migraine headaches in Europe and Africa. 
Since TA has been in clinical use (though not in the US) for decades, the pharmacokinetics 
and toxicity data of this drug are available in both pre-clinical and clinical settings; however, 
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previous studies had a number of limitations, and they were not conducted in models that 
are routinely used for cancer treatment. In this investigation, we have tested the toxicity 
and tolerance of TA using precise laboratory models consistent with pre-clinical screening 
for cancer. Experiments performed in vitro with both normal and malignant cells examined 
the effect of TA on cell viability and the expression of specific molecular markers. Studies in 
athymic nude mice evaluated the effect of TA on animal health and growth, blood chemistry, 
and potential organ damage. These analyses confirmed the specificity of TA in targeting 
cancer cells, and showed that at effective anti-cancer doses, TA does not cause serious 
adverse effects. Further study of TA as an anti-cancer agent is warranted. 
Materials and Methods
Cell lines and reagents
hTERT-HPNE, MiaPaCa-2, Panc1, and SH-SY5Y cells were purchased from ATCC (Manassas, VA). 
Pancreatic cancer cell line L3.6pl was a gift from Dr. Fidler (University of Texas MD Anderson Cancer Center, 
Houston, TX). MiaPaCa-2, Panc1, and L3.6pl cells were cultured in DMEM supplemented with 5% FBS and 
1X Pen-Strep. hTERT-HPNE cells were maintained in media recommended by ATCC (DMEM+M3 Base media 
supplemented with puromycin, HGF, Dextrose, and 5% FBS). SH-SY5Y cells were cultured in EMEM (ATCC) 
supplemented with 5% FBS and 1X Pen-Strep. All cell lines were maintained in a humidified incubator at 
37°C and 5% CO
2
.
Tolfenamic acid, DMSO, and anti-actin antibody were obtained from Sigma (St. Louis, MO), CellTiter-
Glo reagent was from Promega (Madison, WI), anti-Sp1 antibody was purchased from Santa Cruz (Santa 
Cruz, CA), and anti- Survivin was procured from R&D Systems (Minneapolis, MN). Hemoglobin ELISA kit 
was obtained from Abnova (Taipei City, Taiwan).
Cell viability assay
Cells were seeded in a 96-well plate and treated with vehicle (DMSO) or TA (25, 50 and 75 μM). Cell 
viability was measured using CellTiter-Glo kit following the instructions provided by the supplier. Briefly, 
4000 cells were seeded in each well of a white-walled clear bottom 96-well plate and incubated for 24 h in 
a 37°C humidified incubator. Cells were then treated with vehicle (DMSO) or increasing doses of tolfenamic 
acid (0, 25, 50, 75 µM) in triplicate. Following incubation with the drug (24, 48, and 72 h), 100 µl of CellTiter-
Glo reagent was added to each well and the plate was incubated in the dark for 15 minutes. Luminescence 
was measured using a 96-well plate reader (Optima, BMG LABTECH) and cell viability was calculated as the 
percentage of relative luminescence units (RLU) of the drug treated versus vehicle treated cells. Error bars 
represent standard error, which was calculated using statistical tools in MS Office Excel or GraphPad Prism 
(La Jolla, CA). 
Expression of Sp1 and survivin
Expression of Sp1 and survivin in TA treated cells was determined by Western blot analysis. Cells were 
treated with TA (50 µM) for 48 h. Following incubation with TA, cells were washed once with PBS, harvested 
by scrapping, and resuspended in Cell lysis buffer (Invitrogen, Carlsbad, CA). Cells were incubated for 
30 min at 4°C with intermittent mixing followed by centrifugation at 14,000 g for 15 min at 4°C. Protein 
content in the supernatant was estimated using BCA protein assay kit (Pierce, Rockford, IL). Equal amounts 
of protein(s) were separated on 10% SDS-polyacrylamide gels and transferred on to a nitrocellulose 
membranes using iBlot Western Transfer System (Invitrogen, Carlsbad, CA). The membranes were blocked 
with 5% milk and incubated overnight at 4°C, with primary antibody (Sp1, survivin, or actin) followed by 
appropriate HRP-conjugated secondary antibody. Membranes were washed, and the signal was developed 
using Supersignal West Dura (Pierce).
Neuroblastoma cell differentiation studies
Anti-proliferative response of TA was evaluated using differentiated neuroblastoma (NB) cells and 
compared with un-differentiated NB cells. SH-SY5Y cells were seeded in a white-walled clear bottom 
96-well plate (3000 cells/well) and incubated for 24h in a humidified 37°C incubator with 5% CO
2
. Cell 
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differentiation was induced by treating SH-SY5Y cells with 10 µM all-trans-retinoic acid (RA) for 3 days 
following established procedures [40, 41]. Cell count was performed in randomly selected wells and the 
mean value was calculated. Cells equal to this number were seeded in a new plate for control experiments. 
RA treated (differentiated) cells and freshly seeded cells were treated respectively with TA + RA or TA alone 
and cell viability was determined at 24, 48, and 72h post-TA treatment using CellTiter-Glo reagent. 
Growth pattern in athymic nude mice
Nude mice were purchased from Charles River (Wilmington, MA) and maintained at the University 
of Central Florida College of Medicine (AAAS accredited) animal facility, Orlando FL. Animals were treated 
with vehicle (corn oil) or TA (50 mg/Kg) three times a week for 6 weeks through oral gavage. Mice were 
observed throughout the treatment period and the changes in body weight were recorded weekly. At the 
end of the treatment blood was drawn through cardiac puncture (under anesthesia) and used to measure 
hematocrit and plasma hemoglobin. Mice were euthanized and the organs of interest were examined under 
the microscope for overt pathological signs. Liver, intestine and stomach were harvested, cleaned and fixed 
in formalin. 
Hematocrit
The hematocrit test was used to determine the percentage of packed red blood cells in whole blood. 
Blood obtained from cardiac puncture was placed in tubes containing EDTA. Blood was then drawn into 
heparinized microhematocrit capillary tubes. The tubes were placed in a microhematocrit centrifuge and 
spun for 8 to 10 minutes at high speed. Using a hematocrit reader (Critocaps) packed cell volume was 
determined as a percent of the total. 
Hemoglobin ELISA
Hemoglobin levels in control and TA treated mice were determined by a double antibody sandwich 
ELISA kit (Abnova, Taipei City, Taiwan). Briefly, blood was collected into tubes containing heparin and 
carefully centrifuged to avoid hemolysis. Samples were diluted and 100 µl added to each well of a 96-well 
plate pre-coated with anti-hemoglobin antibody. The plate was incubated for an hour at room temperature 
followed by three washes with wash buffer. HRP-conjugated anti-hemoglobin antibody (100 µl) was 
added to each well and incubated for 30 minutes. Wells were washed three times and developed with 
3,3’,5,5’-tetramethylbenzidine (TMB) substrate. The hemoglobin amount in each sample was interpolated 
from a hemoglobin standard curve.
Histopathology assay
Mice tissues (gut, liver, and stomach) were collected at the termination of the experiment and fixed in 
formalin. Paraffin embedded sections (5 µM) were processed for H&E staining in the pathology laboratory 
of Sanford-Burnham Medical Research Institute (Orlando, FL). These stained sections were used for 
histopathological analysis to determine the changes between vehicle and TA treated mice.
Statistical analysis
All quantitative data were expressed as mean±SEM. Statistical comparisons between control and 
drug treated groups were performed using the Student’s t-test and a p value <0.05 was considered to be 
statistically significant.
Results
Tolfenamic acid selectively inhibits pancreatic cancer cell growth 
We have tested the anti-proliferative effect of TA on hTERT-HPNE (Human Pancreatic 
Nestin Expressing) cells and the commonly used pancreatic cancer cells Panc1, L3.6pl and 
MiaPaCa-2. hTERT-HPNE are normal pancreatic duct cells immortalized by transduction with 
the hTERT gene. These cells have been used in various studies as a model for non-malignant 
pancreatic cells. Pancreatic cancer cells and hTERT-HPNE cells were treated with increasing 
concentrations of TA (0/25/50/75 µM) and cell viability was monitored for 3 days (72 h). As 
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presented in Figure 1, TA treatment resulted in a dose and time dependent decrease in cell 
viability of Panc1, L3.6pl, and MiaPaCa-2 cells, however, no significant effect was observed in 
hTERT-HPNE cells. For Panc1, 40.3% and 52.2% cell growth inhibition was observed at 72 
h with 50 and 75 µM TA respectively (Fig. 1b). Conversely, the growth inhibition of hTERT-
HPNE cells was less than 10% with 75 µM of TA (Fig. 1a). Similar to Panc1 cells, other two 
malignant cell lines L3.6pl (Fig. 1c) and MiaPaCa-2 (Fig. 1d) also responded to TA treatment 
exhibiting significant growth inhibition (L3.6pl: 29.0% at 24 h and 64.9% at 72 h; MiaPaCa-2: 
11.4% at 24 h and 43.6% at 72 h with 50 µM TA). 
TA treatment decreases expression of Sp1 and survivin 
Earlier studies demonstrated that TA acts via downregulation of Sp1 transcription factor 
and its downstream targets. Studies from our laboratory have also shown that TA decreases 
survivin expression in some malignant cells. We determined the changes in the expression of 
Fig. 1. Tolfenamic acid inhibits cell viability of Panc1 cells but shows limited response on hTERT-HPNE 
cells. The anti-proliferative response of TA was tested in (a) normal (hTERT-HPNE), and pancreatic cancer 
cells Panc1 (b), L3.6pl (c), MiaPaCa-2 (d). Cells were treated with vehicle (DMSO) or 25/50/75 µM of TA 
and the cell viability was measured using CellTiter-Glo kit (Promega) at 24, 48, and 72 h post-treatment. 
Bars represent mean±SEM of three independent determinations. ‘*’ indicates significantly different from 
corresponding Controls (p<0.05 as evaluated by Students t-test). 
Sp1
Actin
Survivin
hTERT-HPNE
Con      TA
L3.6pl 
Con       TA
MiaPaCa-2
Con       TA
Fig. 2. Tolfenamic acid inhibits the expression of 
Sp1 and survivin in pancreatic cancer cells but not 
in normal cells. Normal pancreatic cells (hTERT-
HPNE), and pancreatic cancer cells (L3.6pl and 
MiaPaCa-2) were treated with vehicle (DMSO) or 
50 μM of TA. Cells were harvested at 48 h post-
treatment and whole cell lysates were prepared and 
the expression of Sp1 and survivin was determined 
by Western blot analysis. Results were obtained 
from at least 3 different experiments. Representative 
gels are shown in the figure and β-actin was used as 
loading control. Con: Control (DMSO treated); TA: 
Tolfenamic acid 50 μM. 
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Sp1 and survivin in the pancreatic cancer cells (L3.6pl and MiaPaCa-2) and normal hTERT-
HPNE cells following 48 h treatment with TA (50 µM). TA treatment did cause a decrease 
in the expression of both Sp1 and survivin in the cancer cells. No effect on Sp1 levels was 
observed in TA-treated hTERT-HPNE cells, and as expected, survivin was not detected in 
these cells (Fig. 2).
Fig. 3. Tolfenamic acid inhibits SH-SY5Y cells with 
limited anti-proliferative response on differentiated 
cells. SH-SY5Y cells were treated with all trans 
retinoic acid (RA) for 3 days and then both un-
differentiated and differentiated (RA treated) 
cells were treated with 0/25/50 µM of TA and the 
cell viability was measured using CellTiter-Glo kit 
(Promega) at 24, 48 and 72 h post-treatment. (a) 
Data represent the mean±SEM of three independent 
determinations and bars marked with ‘*’ are 
significantly different from corresponding controls 
(p <0.05 as evaluated by Students t-test). (b) 
Representative images (10X) for each treatment 
condition. (c) Differentiated SH-SY5Y cells in high 
magnification following RA treatment. Con: Control 
(DMSO treated); RA: Retinoic acid; TA: Tolfenamic 
acid 50 μM. 
Fig. 4. Tolfenamic acid did not change the growth 
pattern or hematocrit and hemoglobin levels in 
mice. Athymic nude mice were treated with 50 
mg/kg TA 3 times/wk for 6 weeks. (a) The growth 
pattern of animals was monitored by measuring 
the body weight changes. Data shown represent the 
mean ±SEM of animal weight (n=6) at each week 
(week 1 through week 6). At the termination of 
the experiment (end of 6th week), blood was drawn 
from the animals (under anesthesia) and used to 
measure (b) hematocrit and (c) plasma hemoglobin 
levels as described in methods section. Bars indicate 
the mean ±SEM (n=4-6). Con: Control group; TA: 
Tolfenamic acid treated group.
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TA treatment has minimal effect on differentiated SH-SY5Y cells
The neuroblastoma cell line SH-SY5Y was grown in the presence of retinoic acid (RA) for 
3 days and regularly observed microscopically. After the confirmation of cell differentiation, 
cells were counted and an equal number of differentiated and un-differentiated cells were 
plated for controlled experiments. Cells were treated with 25 or 50 µM of TA and cell viability 
was measured for 3 days. Interestingly, TA caused a significantly higher growth inhibition 
in un-differentiated SH-SY5Y cells relative to RA treated (differentiated) cells (Fig. 3a). 
The TA-induced growth inhibition was 9.13±0.28% (differentiated) and 27.29±1.77% (un-
differentiated) at 48 h post-treatment; 14.01±2.78% (differentiated) and 35.93±4.39% (un-
differentiated) at 72 h post-treatment. These results demonstrate that the anti-proliferative 
effect of TA was more than double in un-differentiated cancer cells than differentiated cells. 
Chronic TA treatment has no effect on mouse growth, red blood cell count and hemoglobin 
levels
Athymic nude mice were treated with 50 mg/kg TA (3 times/week) for 6 weeks. The 
growth pattern of treated and untreated mice was monitored throughout the study. TA did 
not cause any changes in body weight in any group after 6 weeks (Fig. 4a). At the beginning 
of the study the control group weighed 20.53±0.64 g and the TA-treated group weighed 
20.04±0.43. At the end of the study (after 6 weeks) animals weighed 23.25±0.45 (control) 
and 22.61±0.67 (TA) with an average increase of 2.72 g and 2.57 g respectively. These results 
confirm that TA did not affect the growth pattern of athymic nude mice after treatment up 
to 6 weeks. 
At the termination of the experiment (end of the 6th week), blood was drawn from 
control and TA-treated mice through cardiac puncture. These blood samples were used 
to measure red blood cell count (hematocrit) and plasma hemoglobin levels. Hematocrit 
Fig. 5. Histochemical analysis of mouse gut, stomach and liver following TA treatment for 6 weeks. Athymic 
nude mice were treated with 50 mg/kg TA 3 times/wk for 6 weeks. Control and TA treated mice were 
euthanized after 6 weeks and gut, liver and forestomach tissues were isolated and fixed in formalin. Paraffin-
embedded tissue slides were subjected to H&E staining for histopathological analysis. Representative 
images of (a) gut (intestine), (b) forestomach and (c) liver are shown in the figure. Con: Control group; TA: 
Tolfenamic acid treated group.
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analysis showed that TA treatment had no effect on red blood cell count (Fig. 4b). We also 
measured the hemoglobin levels in the mice blood samples using a hemoglobin ELISA kit 
and found no difference between control and treated groups (Fig. 4c). 
TA treatment did not cause damage to the mouse gut, stomach, and liver
Long term use of NSAIDs is often associated with upper gastrointestinal bleeding and 
ulceration. Stomach (gastric body together with forestomach), intestine tissues, and liver 
were harvested from mice in the 6-week TA-treatment experiment described above. Paraffin 
embedded tissue slices (slides) were prepared, stained with H&E and histopathological 
analysis was performed. Microscopic examination of collected tissues showed no difference 
in the cellular characteristics of control and TA-treated groups. Evaluation of gut (Fig. 5a), 
forestomach (Fig. 5b) and liver (Fig. 5c) revealed no sign of damage or ulceration in TA-
treated mice. 
Discussion
NSAIDs are the most commonly used drugs in clinical practice, generally prescribed for 
pain management. Long term use of specific NSAIDs has been associated with GI injury and 
cardiovascular problems. The anti-inflammatory effect of majority of NSAIDs is primarily 
linked to modulation of COX-1 and COX-2 which catalyze the conversion of arachidonic 
acid to prostaglandins [1]. Since prostaglandins show cytoprotective and antiulcerogenic 
properties in gastric mucosa [42], inhibition of cyclooxygenases decreases prostaglandins 
and results in severe toxicity to GI tract and other vital organs [1, 43]. 
A number of studies have demonstrated the antineoplastic and chemopreventive 
effects of NSAIDs; however the precise mechanisms remain ambiguous. Even though the 
involvement of COX-2 dependent mechanism is relatively well established in the anti-cancer 
activity of NSAIDs, there is increasing evidence for the association of both COX dependent 
and COX-independent pathways [24, 25, 44-47]. Pre-clinical studies from our laboratory 
and others have demonstrated that the anti-cancer activity of TA is mediated through COX-
independent mechanism, and we have shown the involvement of the transcription factor 
Sp1, and an inhibitor of apoptosis protein, survivin. 
In this study, we tested the effect of TA on cell viability in malignant (Panc1, L3.6pl, and 
MiaPaCa-2), and non-malignant (hTERT-HPNE) cells. We found that TA inhibits cancer cells 
but does not cause apparent toxicity in normal cells (Fig. 1). The anti-proliferative effect of 
TA on pancreatic cancer cells was in agreement with the published results [26, 27], showing 
a time/dose-dependent response. In order to correlate such selective cell toxicity, we 
investigated the effect of TA on the expression of Sp1 and survivin (Fig. 2). Cancer cell growth 
inhibition was accompanied with a decrease in the expression of both Sp1 and survivin in 
all three pancreatic cancer cell lines, which is also consistent with published pre-clinical 
work on pancreatic [26] and other cancers [30, 32, 35-37]. Notably, non-malignant hTERT-
HPNE cells do not express survivin but do express Sp1, but TA treatment did not affect the 
expression of Sp1. These results support the idea that TA specifically inhibits cancer cells 
via disruption specific targets, including Sp1 and survivin, and that toxicity through these 
pathways is not discernible in non-malignant cells. 
Recently we showed that TA inhibits neuroblastoma cells SH-SY5Y and LA 155n 
by targeting Sp1 and survivin [36]. We hypothesized that TA effects may be evident 
in undifferentiated and actively growing (malignant) cells, but may not be toxic to 
differentiated cells. To test this hypothesis, we evaluated the anti-proliferative response of 
TA on differentiated and un-differentiated SH-SY5Y cells. Several studies have shown that 
RA induces NB cell differentiation and RA is routinely used to differentiate SH-SY5Y cells 
[40, 41]. We grew these cells in the presence of RA for 3 days, and confirmed differentiation 
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by morphological changes. These cells along with a separate set (equal number) of un-
differentiated SH-SY5Y cells were treated with TA and the anti-proliferative response was 
compared over the period of 3 days (Fig. 3a). As expected, TA caused minimal effect on 
differentiated NB cells when compared to un-differentiated SH-SY5Y cells. Recent studies 
from our group demonstrated that TA induces apoptotic pathways and disrupts cell cycle 
progression in cancer cells [30, 32, 35-37]. It is plausible that apoptotic and cell cycle 
processes/pathways are potentially inactive in differentiated cells, thereby reducing the 
effect of TA in RA treated (differentiated) SH-SY5Y cells. These results further support our 
hypothesis that TA can be toxic to malignant cells which are actively undergoing mitosis but 
is not harmful to differentiated cells or tissues. Thus, the collateral damage of TA may be 
minimal. 
The major limitation for using NSAIDs long-term is their side-effects on the GI tract; 
however other side-effects such as hematological aberrations, hepato and nephro toxicities 
are also observed. In this study we have investigated the overt effect of TA with a maximum 
dose (50 mg/kg 3 times/wk) used in animal cancer models. In previous studies, we have 
given this dose of TA for 4 weeks in mice, however for this study we chose to continue 
the treatment for 6 weeks in order to assess for any pathological changes in the animals. 
We did not find any changes in behavior or growth of TA-treated animals (Fig. 4a). 
Furthermore, hematocrit and hemoglobin levels were unaltered in these animals (Fig. 4 b,c). 
Histopathological analysis also confirmed that TA did not cause any identifiable damage to the 
intestines, stomach (forestomach), or liver (Fig. 5). Prostaglandins ameliorate the balance in 
maintaining the secretions of gastric acid and mucus thereby facilitating the cytoprotection 
of gastric epithelium [48, 49]. It is believed that GI toxicity of NSAIDs is linked to alterations 
of prostaglandin synthesis potentially though perturbations in COX activities [48-50]. Since 
TA works independent of COX, this agent exhibits limited GI disturbances and toxicity. 
Pharmacological analysis has shown that TA has limited toxicity when compared to 
other commonly used NSAIDs [51]. Even though our previous studies using rats showed 
limited toxicity of TA [38], this is the first study assessing the toxicity in detail, achieved 
through putting together the results of animal growth patterns, blood chemistry and organ 
histopathology. All these results showed limited cytotoxicity and GI effects. TA also has an 
excellent therapeutic index in humans [51, 52]. Relatively low GI toxicity could be an added 
advantage for TA when compared to other NSAIDs, apart from its specificity in targeting Sp 
transcription factors and survivin. Tumor cells express higher levels of survivin compared 
to normal cells and over-expression of survivin has been implicated in resistance of cancer 
cells to radiation and chemotherapy. The results of this investigation suggest that TA can act 
as a radiosensitizer due to its specific role on targeting Sp1 and survivin. 
After efficacy, toxicity and side-effects are the key factors that impact the utility of 
therapeutic agents in clinical practice. Investigational agents often fail in clinical testing due 
to high toxicity and/or severe side effects. Our study shows that TA exhibits low toxicity 
and may serve as an ideal partner for use in combination therapy along with radiation or 
other chemotherapeutic drugs. Adding TA as a radio/chemo-sensitizing agent potentially 
facilitates the reduction of the required dose(s) of standard therapy, thereby minimizing 
the adverse side effects associated with aggressive therapy. Considering the characteristic 
potent therapeutic efficacy and low toxicity of TA, further study of this drug as an anticancer 
agent is warranted.
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